// App-Quantinova.ai

: Bay 81-8973 in the Real World: Clinical Effectiveness and Safety in Patients with Hemophilia Α across the US and Europe

Researchers

Presenter

  • Jamie O'Hara

Principal Investigators

  • Ceri Hirst

  • Stephan Rauchensteiner

  • Tom Burke

Medical Centers

  • CEO, HCD Economics Ltd, Warrington, GBR

  • Bayer AG, Basel, Switzerland

  • HCD Economics, Warrington, United Kingdom

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • BAY 81-8973

  • FVIII

Outcome

  • N/A

Study Design

  • Cross-Sectional

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved